Is ATI Positioned for Further Adjusted EBITDA Improvement?

ATI reported Q2 2026 adjusted EBITDA of $284.4 million, up 37% year over year, while adjusted EBITDA margin expanded 440bps to 22.6%. The company raised full-year EBITDA guidance to $1.135-$1.185 billion from $1.010-$1.060 billion and lifted EPS guidance to $4.90-$5.18 from $4.20-$4.48. Record backlog, a higher-margin product mix, long-term customer contracts, and growing content in next-generation aerospace engines and defense programs support continued growth.

Analysis

ATI's incremental guidance reset matters less as a one-quarter earnings event than as evidence that specialty-alloy capacity remains the binding constraint in aerospace and defense. If conversion costs are increasingly absorbed by customers through long-term agreements, ATI can retain pricing while mix shifts toward engine and naval programs; that creates a more durable earnings-quality re-rating than a conventional cyclical metals recovery. CRS is the closest read-through and likely captures the same scarcity premium, while HWM benefits downstream from elevated build rates but has less direct exposure to alloy-price realization.

The near-term risk is that ATI has already discounted much of the operational improvement after its outsized share-price run. A forward sales discount versus broad aerospace peers is not automatically cheap: ATI's lower-margin, more materials-intensive model warrants a discount unless the company demonstrates sustained free-cash-flow conversion, not merely EBITDA expansion. The key 1-3 month catalyst is whether quarterly guidance embeds further price/mix upside; the key falsifier is any evidence of aerospace destocking, customer schedule slippage, or margin dilution from ramp costs and working-capital absorption.

Contrarian view: the more attractive expression may be relative value rather than chasing ATI outright. CRS has potentially cleaner operating leverage to high-value specialty alloys and could close part of its valuation gap if fiscal-2027 profit conversion holds, whereas ATI faces greater expectations risk around its raised outlook. Over 6-18 months, sustained defense propulsion and nuclear demand would tighten qualified-material supply chains, supporting both names, but a commercial-aerospace production pause would expose the cyclicality that backlog alone can obscure.

Key Decisions for Investors

• Initiate a 3-6 month pair: long CRS / short ATI in equal dollar amounts after ATI's post-guidance reaction stabilizes. Thesis is cleaner CRS earnings conversion versus ATI expectation risk; target 10-15% relative outperformance, stop if ATI raises the following-year EBITDA outlook again by more than 10% while CRS fails to reaffirm its operating-income trajectory.
• Keep ATI as a watch-list long rather than add aggressively at current momentum. Buy only on a 10-15% pullback or after evidence that free cash flow and working capital improve alongside margins; target a rerating toward aerospace-material peers over 6-12 months, with exit on a quarterly margin miss or reduced full-year outlook.
• Maintain HWM as the lower-volatility aerospace/defense exposure for a 6-18 month horizon, but do not use it as a pure ATI proxy. HWM's thesis is production-rate and forged-component content, so reduce if commercial-aerospace OEM delivery schedules weaken or gas-turbine demand decelerates.
• Monitor aerospace OEM build-rate revisions, ATI/CRS lead times and inventory commentary at the next earnings cycle. A broad inventory normalization or a sequential decline in realized pricing would invalidate the scarcity-premium thesis and favor reducing specialty-material exposure.